

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Wilson *et al.*  
App. No.: 10/780,296  
Filed: February 17, 2004  
For: A<sub>1</sub> ADENOSINE RECEPTOR ANTAGONISTS

Confirmation No.: 9724  
Group Art Unit: 1624  
Examiner: M. Berch

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

June 6, 2006

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
CITATION UNDER 37 C.F.R. § 1.97**

Sir:

Attached is a list of documents on form PTO-1449 along with a copy of any cited foreign patent documents and non-patent literature documents in accordance with 37 CFR 1.98(a)(2).

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By identifying the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead identifying the listed documents for the sake of full disclosure.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(c), before final Office Action or Allowance, whichever is earlier.

A check for the \$180.00 fee specified in 37 C.F.R. § 1.17(p) is enclosed. The Commissioner is authorized to charge any additional fee, or credit any refund, to our Deposit Account No. 16-0605.

Respectfully submitted,



Jeffrey W. Childers  
Registration No. 58,126

06/08/2006 MAHHE1 00000013 10780296

02 FC:1806

180.00 DP

\* Customer No. 00826  
ALSTON & BIRD LLP  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Raleigh Office (919) 862-2200  
Fax Raleigh Office (919) 862-2260

"Express Mail" mailing label number EV 387075966 US  
Date of Deposit June 6, 2006


I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

  
Lynda Jo Pixley

Substitute for form 1449/PTO  
(Revised 07/2005)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



**Complete if Known**

Application Number	10/780,296
Filing Date	February 17, 2004
First Named Inventor	Wilson
Group Art Unit	1624
Examiner Name	M. Berch
Attorney Docket Number	049542/283879

Sheet 1 of 3

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	1	4,879,296	11-07-1989	Daluge et al.	
	2	5,290,782	3-01-1994	Suzuki et al.	
	3	5,504,090	4-02-1996	Neely, C.F.	
	4	5,733,916	3-31-1998	Neely, C.F.	
	5	5,932,557	8-03-1999	Mustafa et al.	
	6	6,001,842	12-14-1999	Neely, C.F.	
	7	6,117,445	9-12-2000	Neely, C.F.	
	8	2002/0111333 A1	8-15-2002	Lin et al	
	9	2003/0212082 A1	11-13-2003	Linden et al.	
	10	2004/0110774 A1	6-10-2004	Wilson, C.N.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	11	JP 9216883A	8-19-1997	Kuroda et al.		Abstract only
	12	WO 98/03507	1-29-1998	Akahane et al.		
	13	WO 99/67239 A1	12-29-1999	Akahane et al.		
	14	WO 01/34610 A1	5-17-2001	Kiesman et al.		
	15	WO 03/028730 A2	10-04-2003	Novartis AG		

**OTHER DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	16	ALI, <i>et al.</i> , "Adenosine-Induced Bronchoconstriction and Contraction of Airway Smooth Muscle from Allergic Rabbits with Late-Phase Airway Obstruction: Evidence for an Inducible Adenosine A <sub>1</sub> Receptor," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 1993, pp. 1328-1334, Vol. 268(3).	
	17	ANGULO, <i>et al.</i> , "A <sub>1</sub> Adenosine Receptors Accumulate in Neurodegenerative Structures in Alzheimer Disease and Mediate Both Amyloid Precursor Protein Processing and Tau Phosphorylation and Translocation," <i>Brain Pathol.</i> 2003, -pp. 440-451.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/780,296	
				Filing Date	February 17, 2004	
				First Named Inventor	Wilson	
				Group Art Unit	1624	
				Examiner Name	M. Berch	
Sheet	2	of	3	Attorney Docket Number		049542/283879

U. S. PATENT DOCUMENTS						
	18	ASLANIAN, <i>et al.</i> , "Cardiovascular and Pulmonary Diseases," <i>Annual Reports in Medicinal Chemistry</i> , 2001, pp. 32-40, Vol. 36(II), Academic Press, San Diego, CA.				
	19	BALL, <i>et al.</i> , "Clinical Potential of Respirable Antisense Oligonucleotides (RASONS) in Asthma," <i>Am. J. Pharmacogenomics</i> , 2003, pp. 97-106, Vol. 3(2).				
	20	BERTI, <i>et al.</i> , "Pharmacological Activity of Bamifylline on Lung Anaphylaxis: <i>In Vitro</i> Studies," <i>Pharmacological Research</i> , 1990, Vol. 22(2).				
	21	CRONSTEIN, <i>et al.</i> , "Neutrophil Adherence to Endothelium is "Enhanced Via Adenosine A <sub>1</sub> Receptors and Inhibited Via Adenosine A <sub>2</sub> Receptors," <i>The Journal of Immunology</i> , 1992, pp. 2201-2206, Vol. 148.				
	22	CRONSTEIN, <i>et al.</i> , "The Adenosine/Neutrophil Paradox Resolved: Human Neutrophils Possess Both A <sub>1</sub> and A <sub>2</sub> Receptors that Promote Chemotaxis and Inhibit O <sub>2</sub> Generation, Respectively," <i>J. Clin. Invest.</i> , 1990, pp. 1150-1157, Vol. 85.				
	23	DAR, M.S. <i>et al.</i> , "Acute Ethanol / Cannabinoid-Induced Ataxia and Its Antagonism by Oral/Systemic/Intracerebellar A <sub>1</sub> Adenosine Receptor Antisense in Mice," <i>Brain Research</i> , 2002, pp. 53-60, Vol. 957.				
	24	FORMAN, <i>et al.</i> , "Sustained Reduction in Myocardial Reperfusion Injury with an Adenosine Receptor Antagonist: Possible Role of the Neutrophil Chemoattractant Response," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 2000, pp. 929-938, Vol. 292(3).				
	25	GASPARDONE, <i>et al.</i> , "Bamiphylline Improves Exercise-Induced Myocardial Ischemia Through a Novel Mechanism of Action," <i>Circulation</i> , 1993, pp. 502-508, Vol. 88(2).				
	26	GAUBERT, Yves, "Clinical Experience with a New Antispasmodic," <i>Journal De Medicine De Bordeaux</i> , May 1967, pp. 772-776, Vol. 5.				
	27	GOTTLIEB, S.S., <i>et al.</i> , "BG9719 (CVT-124), an A <sub>1</sub> Adenosine Receptor antagonist, Protects Against the Decline in Renal Function Observed with Diuretic Therapy," <i>Journal of American Heart Association</i> , 2002, pp. 1348-1353.				
	28	MARONE, G., <i>et al.</i> , "Adenosine Receptors on Human Leukocytes IV. Characterization of an A <sub>1</sub> /R <sub>1</sub> Receptor," <i>Int. J. Clin. Lab. Res.</i> , 1992, pp. 235242, Vol. 22.				
	29	MARONE, G., <i>et al.</i> , "Adenosine Receptors on Human Inflammatory Cells <sup>1</sup> ," <i>Int. Archs Allergy appl. Immun.</i> , 1985, pp. 259-263, Vol. 77.				
	30	MAYNE, M., <i>et al.</i> , "Dysregulation of Adenosine A <sub>1</sub> Receptor-Mediated Cytokine Expression in Peripheral Blood Mononuclear Cells from Multiple Sclerosis Patients," <i>American Neurological Association</i> , 1999, pp. 633-639.				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/780,296
				Filing Date	February 17, 2004
				First Named Inventor	Wilson
				Group Art Unit	1624
				Examiner Name	M. Berch
Sheet	3	of	3	Attorney Docket Number	049542/283879

U. S. PATENT DOCUMENTS					
	31	NEELY, C.F. <i>et al.</i> , "A <sub>1</sub> Adenosine Receptor Antagonists Block Ischemia-Reperfusion Injury of the Lung," <i>American Physiological Society</i> , 1995, pp. L1036-L1046.			
	32	NEELY, C.F. <i>et al.</i> , "A <sub>1</sub> Adenosine Receptor Antagonists Block Ischemia-Reperfusion Injury of the Heart," <i>American heart Association, Inc.</i> , 1996, pp. II-376-II-380.			
	33	NEELY, C.F. <i>et al.</i> , "A <sub>1</sub> Adenosine Receptor Antagonists Block Endotoxin-Induced Lung Injury," <i>American Physiological Society</i> , 1997, pp. L353-L361.			
	34	MCCOY, D.E., <i>et al.</i> , "Identification and Function of A <sub>1</sub> Adenosine Receptors in Normal and Cystic Fibrosis Human Airway Epithelial Cells," <i>American Physiological Society</i> , 1995, pp. C1520-C1527.			
	35	OBIEFUNA, P.C.M., <i>et al.</i> , "A Novel A <sub>1</sub> Adenosine Receptor Antagonist, L-97-1 [3-[2-(4-Aminophenyl)-ethyl]-8-benzyl-7-(2-ethyl-(2-hydroxy-ethyl)-amino)-ethyl]-1-propyl-3,7-dihydro-purine-2,6-dione], Reduces Allergic Responses to House Dust Mite in an Allergic Rabbit Model of Asthma," <i>The Journal of Pharmacology and</i>			
	36	PANTHER, E., <i>et al.</i> , "Expression and Function of Adenosine Receptors in Human Dendritic Cells," <i>The FASEB Journal</i> , 2001, pp. 1963-1970, Vol. 15.			
	37	SALMON, J.E., <i>et al.</i> , "Human Mononuclear Phagocytes Express Adenosine A <sub>1</sub> Receptors," <i>The Journal of Immunology</i> , 1993, pp. 2775-2785.			
	38	SANTOS, J.M., <i>et al.</i> "Clinical Experimentation with AC 3810 (Trentadil)," <i>Publicado en la Revista Medicina</i> , August 1964, Vol. 8.			
	39	SATO, A., <i>et al.</i> , "Activation of Adenosine A <sub>1</sub> -Receptor Pathway Induces Edema Formation in the Pancreas of Rats," <i>American Gastroenterological Association</i> , 2000, pp. 829-836, Vol. 119.			
	40	VARANI, K., <i>et al.</i> , "Alteration of Adenosine Receptors in Patients with Chronic Obstructive Pulmonary Disease," <i>Am J. Respir Crit Care Med</i> , 2005, pp. 398-406, Vol. 173.			
	41	WEISBERG, S.P., <i>et al.</i> , "Adenosine Receptor Antagonists Inhibit the Development of Morphine Sensitization in the C57BL/6 Mouse," <i>Neuroscience Letters</i> , 1999, pp. 89-92.			
	42	WILSON, C.N., <i>et al.</i> , "Lipopolysaccharide Binds to and Activates A <sub>1</sub> Adenosine Receptors on human Pulmonary Artery Endothelial Cells," <i>Journal of Endotoxin Research</i> , 2002, pp. 1-9, Vol. 8.			

RTA01/2194750v1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.